Jundishapur Journal of Microbiology

Published by: Kowsar

Evaluation of Immune Response Against Inactivated Avian Influenza (H9N2) Vaccine, by Using Chitosan Nanoparticles

Iraj Khalili 1 , * , Rahim Ghadimipour 2 , Saeed Sadigh Eteghad 3 , Mohsen Fathi Najafi 4 , Mohammad Majid Ebrahimi 5 , Naser Godsian 6 , Yousef Sefidi Heris 7 and Mohammad Taghi Khalili 8
Authors Information
1 Laboratory of Virus Biobank, Razi Vaccine and Serum Research Institute, Karaj, IR Iran
2 Department of Research and Development, Razi Vaccine and Serum Research Institute, Ahvaz, IR Iran
3 Neurosciences Research Center, Tabriz University of Medical Science, Tabriz, IR Iran
4 Department of Biotechnology, Razi Vaccine and Serum Research Institute, Mashhad, IR Iran
5 Department of Poultry Research and Vaccine Production, Razi Vaccine and Serum Research Institute, Karaj, IR Iran
6 Department of Poultry Vaccines Quality Control, Razi Vaccine and Serum Research Institute, Karaj, IR Iran
7 Higher Education Institute of Rab-Rashidi, Tabriz, IR Iran
8 Department of Poultry Inactivated Vaccines, Razi Vaccine and Serum Research Institute, Marand, IR Iran
Article information
  • Jundishapur Journal of Microbiology: December 01, 2015, 8 (12); e27035
  • Published Online: December 26, 2015
  • Article Type: Research Article
  • Received: February 6, 2015
  • Revised: March 18, 2015
  • Accepted: April 13, 2015
  • DOI: 10.5812/jjm.27035

To Cite: Khalili I, Ghadimipour R, Sadigh Eteghad S, Fathi Najafi M, Ebrahimi M M, et al. Evaluation of Immune Response Against Inactivated Avian Influenza (H9N2) Vaccine, by Using Chitosan Nanoparticles, Jundishapur J Microbiol. 2015 ; 8(12):e27035. doi: 10.5812/jjm.27035.

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Capua I, Alexander DJ. Avian influenza and Newcastle disease: a field and laboratory manual. 2009; : 1-18[DOI]
  • 2. Hem SL. Elimination of aluminum adjuvants. Vaccine. 2002; 20 Suppl 3-3[PubMed]
  • 3. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998; 15(9): 1326-31[PubMed]
  • 4. Leenaars PP, Hendriksen CF, Koedam MA, Claassen I, Claassen E. Comparison of adjuvants for immune potentiating properties and side effects in mice. Vet Immunol Immunopathol. 1995; 48(1-2): 123-38[PubMed]
  • 5. Hinshaw VS, Webster RG, Easterday BC, Bean WJ. Replication of avian influenza: A viruses in mammals. Infect Immun. 1981; 34(2): 354-61[PubMed]
  • 6. Burleson FG, Chambers TM, Wiedbrauk DL. A laboratory manual London, Virology 1992; : 66-72[DOI]
  • 7. Shu XZ, Zhu KJ. Chitosan/gelatin microspheres prepared by modified emulsification and ionotropic gelation. J Microencapsul. 2001; 18(2): 237-45[DOI][PubMed]
  • 8. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm. 2004; 274(1-2): 1-33[DOI][PubMed]
  • 9. Singh M. Vaccine adjuvants and delivery systems. 2007; : 1-157
  • 10. Yamanaka M, Okabe T, Kodama K, Goto N. Local pathological reactions induced in pigs and cats by adjuvant ISA-70 containing inactivated newcastle disease virus antigen. J Vet Med Sci. 1994; 56(1): 185-7[PubMed]
  • 11. Stills HF. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 2005; 46(3): 280-93[PubMed]
  • 12. Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009; 27(47): 6642-8[DOI][PubMed]
  • 13. Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun. 2000; 68(10): 5764-70[PubMed]
  • 14. Ghendon Y, Markushin S, Krivtsov G, Akopova I. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol. 2008; 153(5): 831-7[DOI][PubMed]
  • 15. Ghendon Y, Markushin S, Vasiliev Y, Akopova I, Koptiaeva I, Krivtsov G, et al. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J Med Virol. 2009; 81(3): 494-506[DOI][PubMed]
  • 16. O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines. 2003; 2(2): 269-83[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments